Advertisements
99% Liraglutide API cas 204656-20-2 Liraglutide powder C172H265N43O51
Price: | US$ 1-500 / Kilogram |
---|---|
Minimum Order: | 1KG |
Payment Terms: | FOB , T/T , L/C , Western union ,money gram |
Port of Export: | SHANGHAI,SHENZHEN |
Product Details
Model No.: | API | Brand Name: | RSN RUISAEN |
---|
Certification: | ISO9001 , SGS, CQM,GMP,HSL,M,HELAL,FAMI-QS. COA,MSDS,Health certificate,BP2010/USP32/EP6 standard |
---|---|
Specification: |
Xi'an Ruisaen Biotechnologh Co., Ltd. 99% Liraglutide API cas 204656-20-2 Liraglutide powder C172H265N43O51 1)Product Name:factory Supply High purity Liraglutide,Cas#204656-20-2, Treatment of diabetic 2)CAS:204656-20-2 3)Molecular Formula:C172H265N43O51 4)Molecular Weight:267.23 5)Assay:99% 6)Appearance:White or colourless crystalline powder with characteristic odor |
Packaging & Delivery
Packaging: | 25kgs packaging Fiber drum outside and plastic bag inside 1-25kgs packaging aluminium bag outside an |
---|---|
Delivery/Lead Time: | Having stock and can ship it out within 3 days when getting the payment. |
Production Capacity: | 2000 Kilogram/Kilograms per Month Coluracetam |
Product Description
Xi'an Ruisaen Biotechnologh Co., Ltd. Liraglutide improves control of blood glucose.It reduces meal-related hyperglycemia (for 24 hours after administration) by increasing insulin secretion (only) when required by increasing glucose levels, delaying gastric emptying, and suppressing prandial glucagon secretion.
In common to various degrees with other GLP-1 receptor agonists, liraglutide has advantages over more traditional therapies for type 2 diabetes:
1).It acts in a glucose-dependent manner, meaning it will stimulate insulin secretion only when blood glucose levels are higher than normal, preventing "overshoot". Consequently, it shows negligible risk of hypoglycemia.
2).It has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies).
3).It decreases appetite and inhibits body weight gain, as shown in a head-to-head study versus glimepiride.
4).It lowers blood triglyceride levels.
Obesity
Liraglutide has been approved as an injectable adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients. The specified criteria are an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight), in the presence of at least one weight-related comorbid condition (e.g.hypertension, type 2 diabetes mellitus, or dyslipidemia). In late 2014, data were reported from the SCALEā¢ Obesity and Prediabetes trial, which is a randomised, double-blind, placebo-controlled, multinational trial in non-diabetic people with obesity and non-diabetic people who are overweight with comorbidities. In this phase 3a trial, there were 3,731 participants randomised to treatment with liraglutide 3 mg or placebo, both in combination with diet and exercise. Those who completed the 56-week trial achieved an average weight loss of 9.2%, to be compared with a 3.5% reduction in the placebo group.
Chris Wenbin
Sales Manager
Xi'an Ruisaen Biotechnologh Co., Ltd.
Add: Room 2305. NO.1/B building ,Fnghuangxincheng. Weiyang district. Xi'an City. Shanxi Province
chris AT rsngov.com
601890126 AT qq.com
S K Y P E qq601333854 AT outlook.com
wechat:xchrisx1
whatsAPP:1362267343
Mobile:+8615379503775
office phone: (+86) 029- 85796727
qq: 601890126
SUPPLIER PROFILE
|
|||
---|---|---|---|
Company: | Xian Ruisaen Biotechnology Co., Ltd. | ||
City/State | XIAN, SHAANXI | Country: | China |
Business Type: | Export - Manufacturer / Trading Company | Established: | 2010 |
Member Since: | 2018 | Contact Person | WEN BIN |
SUPPLIER PROFILE
City/State/Country -
XIAN, SHAANXI
China
Business Type -
Export - Manufacturer / Trading Company
Established -
2010
Member Since -
2018
Contact Person -
WEN BIN